A typical commercial lot is $137,556 a released patient.

Three positions

Start with the lot people already know.

Running at scale takes $15,126 off the typical lot. The vector stays $48,000, and the release method stays compendial. Best-in-class technology takes $61,608 off. The vector on that case is $24,000, half the commercial dose, because the process and the vector technology were chosen to use less. That figure is illustrative. It is a technology specification, not a supplier quote. Failure here is 10%. The cycle is 21 calendar days. Expansion still occupies 7.0 line-days.

Value stream

From the booked slot to the shipped dose.

One patient lot, in the order a commercial autologous process runs. Bar height is the cost of that stage for a typical commercial lot. Color is the kind of activity. Select a stage to open the work underneath it.

The bars are the batch, $123,800. The released-patient figure above is $137,556, which includes a 10% failure load on that whole batch.

Select a stage. The tallest bar is the largest cost on this setting.

The order follows current commercial manufacture and GMP practice. FDA guidance on CAR T cell products expects chain of identity from the leukapheresis material, qualification of incoming materials, in-process control, and release for identity, purity, potency, and safety. EU GMP for ATMPs allows a validated closed system in a Grade D background, and Grade A in a Grade B background when a step is open. The same guideline allows a rapid microbiological method, or certification while compendial sterility is still running, when the product cannot wait. Ayala Ceja and colleagues, Journal of Experimental Medicine (2023), describe the shared spine of approved products: isolation, activation, lentiviral or retroviral transfer, one to two weeks of expansion, formulation, and release, with most products cryopreserved. Luostarinen and colleagues, Scientific Reports (2025), published a 12-day closed GMP run on that same spine, including CD4/CD8 selection and a controlled-rate freeze. ISPE’s 2023 cost discussion treats gowning, cleaning, environmental monitoring, and room grade as costs that move with the protection strategy. Support and overhead on this map are the existing line-day and calendar pools, named as those activities. Rates stay $110 and $160 an hour, $180 a line-hour, $900 a line-day, and $450 a calendar day.

FDA, CAR T cell products guidance · EU GMP for ATMPs · Ayala Ceja et al., 2023 · Luostarinen et al., 2025 · ISPE, 2023

What has been published on the cost

Published automation, on its own, moves a modest slice.

Weltin and colleagues, in Frontiers in Bioengineering and Biotechnology (2026), put one CAR-T treatment at about €63,000 manual, €61,000 semi-automated, and €57,000 fully automated, at that model’s maximum capacity. Materials were 55–70% of the total. The disposable share rose with automation, because the automated platforms used more specialized single-use kits. Their failure rates of 10%, 3%, and 1% are assumptions. The cost advantage showed up above about eight products a year. The technology position on this page goes further than that comparison: it also specifies a cheaper vector and cheaper reagents. That material set is a scenario. The 8% rise in disposables, when the suite closes, is a direction taken from that paper.

Lam, Meinert, Yang, and Cui, in a UK discrete-event case study, put autologous treatment, including the hospital, manufacturing, and transport, at about $70,000 to $167,000 depending on demand and whether the plant was central. Genetic modification was more than a third of their raw-material and consumable cost. Sterility testing sat on the critical path. They cite allogeneic estimates around $4,500 to $8,000. That product serves many patients from one batch.

Weltin et al., 2026 · Lam et al., Oxford case study. Nothing here is a client recipe.

Every unit operation, with labor, line time, indirect, and overhead. The map classifies slot coordination and quality-unit review as indirect. The bill still shows those hours on the labor line. The dollars are the same.